Abstract: The invention relates to pyrosilicate phosphors comprising a coating of aluminum oxide, to a process for the preparation of these compounds, and to the use thereof as conversion phosphors or in lamps.
Type:
Grant
Filed:
March 30, 2016
Date of Patent:
June 23, 2020
Assignee:
Merck Patent GmbH
Inventors:
Aleksander Zych, Ralf Petry, Mathias Rapphahn, Ingo Koehler, Stefan Tews
Abstract: The present invention relates to compounds according to Formula I and pharmaceutically acceptable salts thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.
Type:
Grant
Filed:
March 18, 2019
Date of Patent:
June 23, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Blair T. Lapointe, Peter H. Fuller, Hakan Gunaydin, Kun Liu, Mark E. Scott, B. Wesley Trotter, Hongjun Zhang
Abstract: The present invention relates to microspheres and to the use thereof, preferably as laser-absorbing additive, and to a process for the production thereof.
Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, are useful as BTK inhibitors.
Type:
Grant
Filed:
September 23, 2019
Date of Patent:
June 23, 2020
Assignee:
Merck Patent GmbH
Inventors:
Axel Becker, Marco Poma, Edoardo Burini, Christoph Saal, Vedad Theuerkorn
Abstract: Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.
Type:
Grant
Filed:
May 23, 2017
Date of Patent:
June 23, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Songnian Lin, Lin Yan, Pei Huo, Dmitri Pissarnitski, Danqing Feng, Ravi Nargund, Christina Madsen-Duggan, Yuping Zhu, Ahmet Kekec, Zhicai Wu
Abstract: The present application discloses a switchable device, comprising a switching layer and a first conductive layer and a second conductive layer, where the switching layer is positioned between the first and the second conductive layer, and where at least one of the first and the second conductive layers comprises a plurality of isolating sections and a plurality of conductive sections, where the isolating sections and the conductive sections alternate over the area of the conductive layer, and where the switching state of the switchable device is controlled by touch motions.
Type:
Grant
Filed:
December 22, 2015
Date of Patent:
June 23, 2020
Assignee:
Merck Patent GmbH
Inventors:
Ties De Jong, Casper Laurens Van Oosten, Felix Fritz Rudolf Schlosser
Abstract: Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: “Z”, R1 and R2 are defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.
Type:
Grant
Filed:
June 6, 2016
Date of Patent:
June 23, 2020
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Junying Zheng, Walter Won, Michael Berlin, Pauline Ting, Guoqing Li, Dong Xiao, Hongwu Wang, Robert Aslanian
Abstract: The present invention relates to colored effect pigments, in particular to those containing an organic color pigment layer, to a preparation method thereof and to the use of these pigments especially in a composition comprising the colored effect pigments.
Abstract: The present invention relates to organic electronic devices, and more specifically to organic field effect transistors, comprising a dielectric layer that comprises a polycycloolefinic polymer and a diazirine compound.
Type:
Grant
Filed:
January 25, 2019
Date of Patent:
June 23, 2020
Assignees:
PROMERUS, LLC, MERCK PATENT GMBH
Inventors:
Larry F Rhodes, Hugh Burgoon, Irina Afonina, Tomas Backlund, Aurelie Morley
Abstract: The present invention relates to compounds of the formula (I) (Rf-CHF—CF2—CHR)m-L-(X)n, where Rf=a perfluorinated alkyl group, optionally containing heteroatoms, R=H or an alkyl group, L=a single bond or a divalent organic group, X=an anchor group, m is ?1 and n is ?1, and to the use thereof in, for example, dirt-repellent coatings.
Abstract: The present invention relates to novel Inclusion Complexes of Compound A, compositions comprising an Inclusion Complex of Compound A, and methods of using the Inclusion Complexes of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure:
Type:
Application
Filed:
December 11, 2019
Publication date:
June 18, 2020
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Michael J. McNevin, Alfred Lee, Jason T. Ash, Itzia Arroyo, Binfeng Xia
Abstract: The present invention relates to immunoglobulins that specifically bind MMP13 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the immunoglobulins of the present invention inhibit an activity of MMP13 and preferably are also stable.
Type:
Application
Filed:
June 4, 2018
Publication date:
June 18, 2020
Applicants:
Merck Patent GmbH, ABLYNX NV
Inventors:
Francis DESCAMPS, Gerald BESTE, Guy HERMANS, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL
Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
Type:
Application
Filed:
February 20, 2020
Publication date:
June 18, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
Abstract: The present invention relates to Mn4+-activated luminescent materials, to a process for the preparation thereof, and the use thereof as phosphors or conversion phosphors in light sources. The present invention furthermore relates to an emission-converting material comprising the luminescent material according to the invention, and to a light source which comprises the luminescent material according to the invention or the omission-converting material. The present invention furthermore relates to light sources, in particular LEDs, and lighting units which contain a primary light source and the luminescent material according to the invention or the emission-converting material. The Mn4+-activated luminescent materials according to the invention are suitable, in particular, for the generation of warm-white light in LEDs.
Type:
Application
Filed:
October 9, 2017
Publication date:
June 18, 2020
Applicant:
Merck Patent GmbH
Inventors:
Ralf PETRY, Ingo KOEHLER, Mathias RAPPHAHN, Thomas JUESTEL, Thomas JANSEN
Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
Type:
Application
Filed:
February 20, 2020
Publication date:
June 18, 2020
Applicant:
MERCK PATENT GMBH
Inventors:
Dieter DORSCH, Mathilde MUZERELLE, Lars BURGDORF, Margarita WUCHERER-PLIETKER, Paul CZODROWSKI, Christina ESDAR, Christos TSAKLAKIDIS
Abstract: The present invention relates to soluble organic compounds, to compositions comprising these compounds, to formulations comprising the compounds or compositions, and to electronic devices.
Type:
Grant
Filed:
November 18, 2015
Date of Patent:
June 16, 2020
Assignee:
Merck Patent GmbH
Inventors:
Amir Hossain Parham, Philipp Stoessel, Christof Pflumm, Anja Jatsch, Joachim Kaiser, Ewald Aydt, Dominik Joosten
Abstract: The invention relates to formulations comprising at least two organic semiconducting compounds and at least two solvents, methods for their preparation, their use for the preparation of electronic devices and electronic devices comprising organic semiconducting materials.
Abstract: The present invention relates to a cell-based reporter assay for determining viral potency comprising A) transfecting cells maintained in media with a promoter-reporter construct and generating reporter enzyme within the cells; B) infecting cells with a live virus or live virus vaccine wherein reporter enzyme is released into media; and C) measuring reporter enzyme intensity in media.
Type:
Application
Filed:
December 11, 2017
Publication date:
June 11, 2020
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
BRIAN K. MEYER, AKHILESH BHAMBHANI, JEFFREY T. BLUE
Abstract: The present invention relates to long-acting implants useful for the treatment of bacterial infections, particularly mycobacterial infections. The invention also relates to methods of use of such long-acting implants for the treatment of mycobacterial infections such as those caused by Mycobacteria tuberculosis.
Type:
Application
Filed:
June 1, 2018
Publication date:
June 11, 2020
Applicant:
Merck Sharp & DohmeCorp
Inventors:
Stephanie Elizabeth Barrett, Seth P. Forster, Marian E. Gindy, Jay A. Grobler, David Brian Olsen, Ryan Stevenson Teller